The impact of the mediterranean diet and lifestyle intervention on lipoprotein subclass profiles among metabolic syndrome patients: Findings of a randomized controlled trial

Candás-Estébanez, Beatriz; Fernández-Cidón, Bárbara; Corbella, Emili; Tebé, Cristian; Fanlo Maresma, Marta; Esteve Luque, Virginia; Salas Salvadó, Jordi; Fitó Colomer, Montserrat; Riera-Mestre, Antoni; Ros, Emilio; Pintó Sala, Xavier

doi:http://dx.doi.org/10.3390/ijms25021338

The impact of the mediterranean diet and lifestyle intervention on lipoprotein subclass profiles among metabolic syndrome patients: Findings of a randomized controlled trial

Llicència

Citació

Candás-Estébanez B, Fernández-Cidón B, Corbella E, Tebé C, Fanlo-Maresma M, Esteve-Luque V, et al. The impact of the mediterranean diet and lifestyle intervention on lipoprotein subclass profiles among metabolic syndrome patients: Findings of a randomized controlled trial. Int J Mol Sci. 2024 Jan 22;25(2):1338. DOI: 10.3390/ijms25021338

Resum

Metabolic syndrome (MetS) is associated with alterations of lipoprotein structure and function that can be characterized with advanced lipoprotein testing (ADLT). The effect of the Mediterranean diet (MedDiet) and weight loss on the lipoprotein subclass profile has been scarcely studied. Within the PREDIMED-Plus randomized controlled trial, a sub-study conducted at Bellvitge Hospital recruiting center evaluated the effects of a weight loss program based on an energy-reduced MedDiet (er-MedDiet) and physical activity (PA) promotion (intervention group) compared with energy-unrestricted MedDiet recommendations (control group) on ADLT-assessed lipoprotein subclasses. 202 patients with MetS (n = 107, intervention; n = 95, control) were included. Lipid profiles were determined, and ADLT was performed at baseline, 6, and 12 months. Linear mixed models were used to assess the effects of intervention on lipoprotein profiles. Compared to the control diet, at 12 months, the er-MedDiet+PA resulted in a significant additional 4.2 kg of body weight loss, a decrease in body mass index by 1.4 kg/m2, reduction in waist circumference by 2.2 cm, decreased triglycerides, LDL-cholesterol and non-HDL-cholesterol, and increased HDL-cholesterol. In er-MedDiet+PA participants, ADLT revealed a decrease in small dense-LDL-cholesterol (sd-LDL-C), intermediate-density lipoproteins, VLDL-triglyceride, and HDL-Triglyceride, and an increase in large LDL and large VLDL particles. In conclusion, compared to an ad libitum MedDiet (control group), er-MedDiet+PA decreased plasma triglycerides and the triglyceride content in HDL and VLDL particles, decreased sd-LDL-C, and increased large LDL particles, indicating beneficial changes against cardiovascular disease.